Cetuximab: its unique place in head and neck cancer treatment
Pol Specenier, Jan B Vermorken Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium Abstract: Head and neck cancer is the sixth most common cancer worldwide. At present, globally about 650,000 new cases of squamous cell carcinoma of the head and neck (SCCHN) are diagnosed eac...
Guardado en:
Autores principales: | Specenier P, Vermorken JB |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/63dc4cfc92194dbf86985b7256dbdf08 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer
por: Mohamedtaki A Tejani, et al.
Publicado: (2010) -
Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
por: Shinsuke Suzuki, et al.
Publicado: (2021) -
Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy
por: Tseng SH, et al.
Publicado: (2015) -
Role of CD44 as a marker of cancer stem cells in head and neck cancer
por: Trapasso S, et al.
Publicado: (2012) -
EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
por: Chad A Reade, et al.
Publicado: (2009)